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INTRODUCTION
Tuberculous pleural effusion (TPE) occurs because of a
delayed hypersensitivity reaction to mycobacterial antigens
rather than an infectious process (1). Despite the introduc-
tion of a standard antituberculous medication, this condi-
tion is known to leave pleural thickening in a significant
proportion of observed cases (2-5). The benefit of the efforts
to reduce residual pleural thickening (RPT), such as adjunc-
tive therapy of corticosteroids or pigtail drainage, remains
inconclusive (4, 6, 7).
It has long been an issue of interest to have the capability
to predict the development of RPT in TPE (8). The earliest
study regarding factors influencing RPT in TPE, to our knowl-
edge, failed to demonstrate which patients would have the
sequela from either their clinical characteristics or pleural
fluid findings (3). In contrast, the following studies suggested
that some parameters in pleural fluid analysis differed
between patients with and without RPT (2, 3, 8), while the
results of these studies were not replicable in another study
(9). Accordingly, factors determining RPT in TPE still remain
to be elucidated. 
The presence or absence of RPT was determined by the
pleural based opacity on chest radiographs, which comprised
nonresolving pleural effusion as well as true pleural thicken-
ing. Thus, residual pleural opacity (RPO) is considered to be
more proper rather than RPT, as described by Han et al. (5). 
The aim of this study was to investigate the factors influ-
encing RPO after treatment of TPE. Unlike previous stud-
ies, we used computed tomography (CT) images rather than




The study population comprised HIV-negative patients
with TPE admitted to Kyungpook National University
Hospital (Daegu, Korea) between September 2004 and July
2006. On the first day of hospitalization, pleural fluid sam-
ples were obtained from the patients and subjected to rou-
tine analysis including cell count with differentials, pH,
lactate dehydrogenase (LDH), glucose, and protein. Pleural
fluid adenosine deaminase (ADA) activity was determined
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Factors Influencing Residual Pleural Opacity in Tuberculous Pleural
Effusion
Tuberculous pleural effusion (TPE) leads to residual pleural opacity (RPO) in a sig-
nificant proportion of cases. The aim of this study was to investigate which TPE
patients would have RPO following the treatment. This study was performed prospec-
tively for a total of 60 TPE patients, who underwent pleural fluid analysis on the ini-
tial visit and chest radiographs and computed tomography (CT) scans before and
after the administration of antituberculous medication. At the end of antitubercu-
lous medication, the incidence of RPO was 68.3% (41/60) on CT with a range of
2-50 mm. Compared with the non-RPO group, the RPO group had a longer symp-
tom duration and lower pleural fluid glucose level. On initial CT, loculation, extrapleu-
ral fat proliferation, increased attenuation of extrapleural fat, and pleura-adjacent
atelectasis were more frequent, and parietal pleura was thicker in the RPO group
compared with the non-RPO group. By multivariate analysis, extrapleural fat prolif-
eration, loculated effusion, and symptom duration were found to be predictors of
RPO in TPE. In conclusion, RPO in TPE may be predicted by the clinico-radiologic
parameters related to the chronicity of the effusion, such as symptom duration and
extrapleural fat proliferation and loculated effusion on CT. 
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according to the colorimetric method described by Giusti
and Galanti (10). Microbiological studies, such as acid-fast
bacilli (AFB) smear and mycobacterial culture and cytologi-
cal examination were performed. In addition, all patients
underwent Mycobacterium tuberculosis polymerase chain reac-
tion (PCR) using the Cobas Amplicor MTB test (Roche
Diagnostic System, Basel, Switzerland) (11). TPE was diag-
nosed if at least one of the following criteria was fulfilled: 1)
positive AFB smear or culture of M. tuberculosis in pleural
fluid; and 2) chronic granulomatous inflammation on pleu-
ral biopsy specimen. 
All patients received antituberculous medication for the
first two months of the study as follows: isoniazid 300 mg/
day; rifampin, 600 mg/day (450 mg/day for patients with
<50 kg of body weight); ethambutol 1,200 mg/day (800 mg/
day for patients with <50 kg of body weight); and pyrazi-
namide 1,500 mg/day (1,000 mg/day for patients with <50
kg of body weight). Subsequently the next four months in-
cluded treatment with isoniazid 300 mg/day; rifampin 600
mg/day (450 mg/day for patients with <50 kg of body weight);
and ethambutol 800 mg/day, but pyrazinamide was discon-
tinued. After obtaining the necessary samples, pleural fluid
was drained as completely as possible by thoracentesis. This
study was approved by our institutional review board and
written informed consent was obtained from all patients to
be enrolled. 
Radiologic analysis
Chest radiographs and CT scans, obtained before and after
treatment, were separately analyzed by an experienced tho-
racic radiologist. Chest radiographs were taken on a month-
ly basis during follow-up until the end of antituberculous
medication. The posteroanterior chest radiographs initially
determined the amount of pleural effusion by modification
of Han et al. (5) as follows: small, the level of pleural effusion
which blunted the costophrenic angle but did not obscure
the entire diaphragm; moderate, the level which obscured
the entire diaphragm but below the hilum; and large, the
level up to and above the hilum. For quantitative assessment
of RPO at the completion of antituberculosis medication,
we measured the distance from the lateral chest wall to the
innermost margin of the opacity at the level of the highest
point of the hemidiaphragm. However, in patients with lat-
erally formed loculations, the maximum horizontal thick-
ness of lateral loculations was measured instead. 
CT scan of the chest was performed with intravenous con-
trast enhancement. At initial CT scans, loculation or free col-
lection of the fluid, presence of pleural thickening, extrapleu-
ral fat proliferation, increased attenuation of extrapleural fat,
circumferential pleural thickening, and parenchymal lesions
such as cavity, consolidation, centrilobular nodules were ob-
served (Fig. 1). If pleural thickening was noted, measure-
ment of pleural thickness was followed. After medication,
RPO thickness which comprised pleural thickness and non-
resolving pleural effusion were measured and the presence
of pleural or subpleural mass-like lesions was observed.
Statistical analysis
Statistical analyses were performed using SPSS software
(Version 12.0; SPSS Inc, Chicago, IL, U.S.A.). Data were ex-
pressed as mean±standard deviation (SD) or median with
interquartile range (IQR; 25% and 75%), if the data were
skewed, for continuous variables, and percentages for cate-
gorical variables. Between two groups, continuous variables
were compared by Student’s t-test and Mann-Whitney U
test if non-normally distributed, whereas categorical ones
were compared using a chi-squared test or Fisher’s exact test.
Multiple logistic regression analysis was performed to eval-
uate the variables determining RPO. Two-sided p values
<0.05 was considered to be statistically significant.
Fig. 1. (A) Initial chest computed tomography (CT) scan shows loculated pleural fluid, accumulated in nondependent portion, and marked
circumferential pleural thickening on the left. (B) Enhanced chest CT reveals pleural fluid collection with enhanced, thickened pleura on
the left. Extrapleural fat proliferation (> 3 mm, arrows) and increased attenuation of extrapleural fat (a long arrow) are noted. 
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RESULTS
Baseline characteristics
During the study period, 78 patients with TPE were enroll-
ed in this study; 18 patients were excluded due to loss to
follow-up (n=13) and the change of antituberculous drugs
because of adverse effects or drug-resistance (n=5). Conse-
quently, 60 patients were available to the final analysis. The
demographic data are summarized in Table 1. The incidence
of RPO at the completion of antituberculous medication was
68.3% (41/60) on CT scan and 63.3% (38/60) on chest radio-
graph. The ranges of RPO on CT and chest radiograph were
2-50 mm and 3-70 mm, respectively. The subjects were divid-
ed into the patients with and without RPO on CT scan (RPO
group vs. non-RPO group). The RPO group had a longer
symptom duration (median [IQR], 14 days [7-30] vs. 7 days
[6-14]; p=0.031) and tended to be predominant in males
(male-to-female, 30/11 vs. 9/10; p=0.051) compared with
the non-RPO group. For symptomatic relief of high fever
or dyspnea due to paradoxical reaction, corticosteroids (≥
prednisolone 15 mg/day for at least 10 days) and therapeu-
tic thoracentesis or pleural drainage were used with similar
frequency in both groups. In the remaining variables, no sig-
nificant differences were observed between the two groups.
Pleural fluid analysis 
A significantly lower glucose level in pleural fluid was
observed in the RPO group compared with in the non-RPO
group (median [IQR], 83 mg/dL [67-103] vs. 115 mg/dL
[91-123]; p=0.003) (Table 2). The RPO group tended to
have a lower pleural fluid cell count (median [IQR], 2,300/
μ L [1,100-4,600] vs. 3,500/μ L [2,800-5,500]; p=0.054) and
lower pH level (median [IQR], 7.41 [7.35-7.44] vs. 7.44
[7.38-7.46]; p=0.055). No significant differences in LDH,
protein, and ADA levels of pleural fluid were noted between
the two groups. Overall, no patient was positive for the pleu-
ral fluid AFB smear and M. tuberculosis-PCR testing. M. tuber-
culosis was cultured in five cases from the RPO group but no
significant difference was observed between the RPO and
non-RPO groups. 
Radiographic findings
The results of the radiologic analyses are presented in Table
3. No differences between both groups were observed in the
parameters of chest radiographic features. Among initial CT
findings, loculation, extrapleural fat proliferation, increased
attenuation of extrapleural fat, and pleura-adjacent atelectasis
were more frequently seen (41.5% [17/41] vs. 10.5% [2/19],
p=0.017; 70.7% [29/41] vs. 31.6% [6/19], p=0.004; 31.7%
[13/41] vs. 5.3% [1/19], p=0.024; and 24.4% [10/41] vs.
0.0% [0/19], p=0.018) and pleural thickness (3.6±1.4 mm
vs. 2.7±0.9 mm; p=0.023) was significantly higher in the
RPO group compared with the non-RPO group. The patients
with RPO tended to have frequent circumferential pleural
thickening on CT scan (14.6% [6/41] vs. 0.0% [0/19], p=
0.079). The frequency of pleural mass and other lung paren-
chymal findings, including pulmonary cavities, centrilobu-
lar nodules, and consolidation was not significantly differ-
ent between the two groups. 
Multivariate analysis for predictors of residual pleural
opacity on CT scans
As the data of symptom duration was skewed and non-nor-







Gender, M/F 30/11 9/10 0.051
Age (yr) 44 (29-64) 53 (29-71) 0.324
Smoking
Smoking status 0.327
Ever smokers 15 (36.6) 9 (47.4)
Never smokers 26 (63.4) 10 (52.6)
Pack-years 25 (25-50) 20 (12-32) 0.258
Presenting symptoms 0.768
Chest pain 16 (39.0) 8 (42.1)
Dyspnea 14 (34.1) 6 (31.6)
Cough 5 (12.2) 4 (21.1)
Fever 5 (12.2) 1 (5.3)
Chest radiographic  1 (2.4) 0 (0.0)
abnormalities
Symptom duration, days 14 (7-30) 7 (6-14) 0.031
Paradoxical reaction 8 (19.5) 1 (5.3) 0.150
Corticosteroids* 4 (9.8) 2 (10.5) 0.926
Therapeutic thoracentesis 1 (2.4) 1 (5.3) 0.571
Table 1. Demographics of study population (n=60)
Values are median (interquartile range) or numbers (%). 
*, ≥prednisolone 15 mg/day for at least 10 days. 







Cell count ( /μ L) 2,300 (1,100-4,600)  3,500 (2,800-5,500) 0.054
pH 7.40±0.098 7.43±0.065 0.232
Glucose (mg/dL) 83 (67-103) 115 (91-123) 0.003
LDH (U/L) 1,308±967.7 934±571.3 0.124
Protein (g/L) 5.5±0.66 5.6±0.36 0.412
ADA (IU/L) 98±33.3 112±47.6 0.195
AFB smear 0 (0.0) 0 (0.0) -
AFB culture 5 (12.2) 0 (0.0) 0.112
M. tuberculosis PCR 0 (0.0) 0 (0.0) -
Table 2. Pleural fluid characteristics (n=60)
Values are median (interquartile range), mean±SD, or numbers (%). 
RPO, residual pleural opacity; LDH, lactate dehydrogenase; ADA, adeno-
sine deaminase; AFB, acid-fast bacilli; PCR, polymerase chain reaction.Residual Opacity in Tuberculous Pleurisy 619
nal one by stratifying into four levels: 0 to 9 days, 10 to 19
days, 20 to 29 days, and ≥30 days. Multiple logistic regres-
sion analysis demonstrated that the presence of extrapleural
fat proliferation (odds ratio [OR], 5.642; 95% confidence
interval [CI], 1.342-23.723; p=0.018) and loculated effusion
on CT scan (OR, 6.795; 95% CI, 1.025-45.055; p=0.047)
and symptom duration (OR, 1.996; 95% CI, 1.067-3.733;
p=0.030) were the predictors of RPO on CT scan in TPE
(Table 4).
DISCUSSION
Clinical parameters of symptom duration, a pleural fluid
constituent of low glucose level, and CT features of pleural
thickness and the presence of loculated effusion, extrapleu-
ral fat proliferation, increased attenuation of extrapleural fat,
and pleura-adjacent atelectasis were significantly different
between the RPO and non-RPO groups. Multivariate anal-
ysis revealed that clinically, symptom duration and radiolog-
ically, extrapleural fat proliferation and loculation on CT before
the start of antituberculous medication might be predictive
of RPO at the end of the medication in TPE patients. These
three parameters commonly make a suggestion of a long-
standing pleural effusion, indicating that RPO in TPE may
be influenced by the chronicity rather than the intensity of
pleural effusion. From this perspective, early diagnosis and
early initiation of antituberculous medication is expected to
reduce the development of RPO in patients with TPE (2, 7). 
The parietal pleura consists anatomically of four major
layers as follows: beginning with the innermost layer, 1) a
single layer of mesothelial cells; 2) a thin supportive fibroe-
lastic layer; 3) a layer of loose connective tissue; and 4) the
endothoracic fascia, a second fibroelastic layer that tethers
the pleura to the overlying ribs (12). In normal condition,
these layers are quite thin, except for the layer of loose con-
nective tissue (12, 13), where the fat is referred to as ‘‘subpleu-
ral’’ or ‘‘extrapleural’’ (13). Extrapleural fat proliferation or
thickening is frequently noted in patients with chronic empye-
ma (14, 15). This CT finding, therefore, appears to reflect
that the pleural inflammation in parapneumonic effusion
and TPE persists for a fairly long time rather than a short
period. Increased attenuation of extrapleural fat, not specific
to empyema, was also seen in approximately 75% of patients
with the late fibropurulent and organizing stages of parap-
neumonic effusion/empyema, signifying an ongoing inflam-
matory process infiltrating extrapleural space (14, 15). In a
CT-pathologic correlation study, increased attenuation of
extrapleural fat corresponded histopathologically to the layer
of proliferation of vessels, inflammatory cells, and granulo-
mas (15). In this study, although both extrapleural fat pro-
liferation and increased attenuation of extrapleural fat sig-
nificantly differed between the two groups in the univariate
analyses, only extrapleural fat proliferation turned out to be
a predictor of RPO with an OR of 5.6 in the multivariate
analysis. We speculate that extrapleural fat proliferation may
indicate the chronicity of pleural disease, while increased
attenuation of extrapleural fat may suggest active inflamma-
tion spreading to extrapleural space.
Next, CT is particularly helpful in the assessment and
management of loculated pleural effusions (16). A previous
study suggested that patients with a loculated effusion may
have a more protracted course (13). Loculation on CT also
implies the chronicity of the pleural effusion. Furthermore,
longer symptom duration was a marginal but significant pre-
dictor on the formation of TPE, which supports the results
of the study by Barbas et al. (3, 17). 
The importance of the chronicity of pleural inflammation








Right vs. left 27/14 11/8 0.552




Loculated effusion 16 (39.0) 3 (15.8) 0.072
Initial CT findings
Loculated effusion 17 (41.5) 2 (10.5) 0.017
Pleural thickening  41 (100.0) 18 (94.7) 0.139
Pleural thickness (mm) 3.6±1.4 2.7±0.9 0.023
Circumferential pleural 6 (14.6) 0 (0.0) 0.079
thickening
Extrapleural fat proliferation 29 (70.7) 6 (31.6) 0.004
Increased attenuation of 13 (31.7) 1 (5.3) 0.024
extrapleural fat
Pulmonary cavity 1 (2.4) 0 (0.0) 0.492
Consolidation 10 (24.4) 2 (10.5) 0.212
Centrilobular nodule 13 (31.7) 6 (31.6) 0.992
Pleura-adjacent atelectasis 10 (24.4) 0 (0.0) 0.018
Round atelectasis 2 (4.9) 0 (0.0) 0.327
Follow-up CT finding
Pleural or subpleural mass 12 (29.3) 3 (15.8) 0.346
Table 3. Chest radiographic and computed tomographic fea-
tures (n=60)
Values are median (interquartile range), mean±SD, or numbers (%). 
RPO, residual pleural opacity; CT, computed tomography. 
Variables Variables ORs (95% CI) p value
Symptom duration* 1.996 (1.067-3.733) 0.030
Extrapleural fat proliferation on CT 5.642 (1.342-23.723) 0.018
Loculated effusion on CT 6.795 (1.025-45.055) 0.047
Table 4. Multiple logistic regression analysis
*Symptom duration was stratified into 4 levels by a unit of 10 days: 0 to
9 days, 10 to 19 days, 20 to 29 days, and ≥30 days.
OR, odds ratio; CI, confidence interval; CT, computed tomography.620 J.-S. Kwon, S.-I. Cha, K.-N. Jeon, et al.
studies (9, 18). Candela et al. reported that, with respect to
the pleural fluid constituents, only the lipid components
showed an apparent influence on the development of func-
tional sequelae of TPE (18). In the other study, the extent of
RPT was not correlated with the levels of interleukin-6, tumor
necrosis factor-α , and interferon-γin the initial pleural fluid
sample. However, for those 11 patients with paired samples,
a significant negative correlation between the percentage
reduction in the levels of cytokines and the eventual extent
of RPT was found. These data possibly suggest a more like-
ly association of RPT with the rate of resolution of pleural
inflammation rather than the intensity of inflammation at
presentation (9).
The present study had several limitations. The prevalence
of RPO in the present study was higher compared with pre-
vious studies (2-4, 7, 17, 18). We cannot explain this appro-
priately although there was a possibility that it originated
from selection bias. Furthermore, RPO on chest radiograph,
exaggerated by pleura-adjacent lung atelectasis, extrapleural
fat, and pleural mass lesion (data not shown), was thicker than
that on CT (3-70 mm vs. 2-50 mm). Secondly, as improve-
ment of RPO often occurred even after completion of anti-
tuberculous medication up to 24 months (5), RPO in this
study may be different from RPO at a final stage. However,
considering that RPO at the end of antituberculous medi-
cation was strongly correlated with that at 24 months, RPO
in this study is thought to reflect the final RPO. Lastly, pul-
monary function test was not included in the present study
and functional sequelae could not be estimated. Therefore, the
extent of functional limitation in patients with RPO was not
identified.
In conclusion, RPO in TPE may be determined by the
clinico-radiologic parameters related to the chronicity of the
effusion as a function of symptom duration and radiological
extrapleural fat proliferation and loculated effusion on CT.
Therefore, early diagnosis and early treatment may be impor-
tant to reduce the incidence of the RPO in patients with TPE.
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